- Molecular NameCinoxacin
- SynonymNA
- Weight262.221
- Drugbank_IDDB00827
- ACS_NO28657-80-9
- Show 2D model
- LogP (experiment)1.66
- LogP (predicted, AB/LogP v2.0)1.23
- pkaN/A
- LogD (pH=7, predicted)-2.16
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.12
- LogSw (predicted, AB/LogsW2.0)0.35
- Sw (mg/ml) (predicted, ACD/Labs)0.88
- No.of HBond Donors1
- No.of HBond Acceptors7
- No.of Rotatable Bonds2
- TPSA88.43
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn older synthetic antimicrobial related to the quinolone class of antibiotics with activity similar to Oxolinic Acid and Nalidixic Acid. It was commonly used thirty years ago to treat urinary tract infections in adults. There are reports that cinoxacin had also been used to treat initial and recurrent urinary tract infections and bacterial prostatitis in dogs
- Absorption_value95.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability72.0
- Protein binding70.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmBiotransformation is mainly hepatic, with approximately 30-40% metabolized to inactive metabolites.
- Half life1.5 h
- ExcretionAbout 30 to 75% of a single dose is excreted in urine as the unchanged drug (20 to 25% of total excreted) and as glucuronide conjugates, in 72 h. It is not removed by dialysis.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms following an overdose of cinoxacin may include anorexia, nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have been reported in some patients.
- LD50 (rat)Oral, subcutaneous, and intravenous LD50 in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively
- LD50 (mouse)Oral, subcutaneous, and intravenous LD50 in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg